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Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight? 
 
 High-grade osteosarcoma (HGOS) is the most common malignant tumour of bone. One of 
the most active drugs for HGOS treatment is doxorubicin, which is invariably included in HGOS 
chemotherapy protocols together with methotrexate and cisplatin, with the possible addition of 
ifosfamide. Several studies have shown that HGOS patients may be inherently resistant to 
doxorubicin or may become unresponsive to this drug during chemotherapeutic treatment [1, 2]. 
The most relevant mechanism of doxorubicin resistance in HGOS has been demonstrated to be the 
ATP-binding cassette (ABC) transporters-mediated drug efflux, with ABCB1 (P-glycoprotein, 
MDR1) playing a predominat role [2, 3]. Furthermore, ABCB1 overexpression has been reported 
independently by several authors to be associated with an adverse clinical outcome [1, 2]. Based 
on this evidence, in 2011, the evaluation of ABCB1 protein expression level at diagnosis has been 
introduced to tailor the treatment of HGOS patients according to their ABCB1 expression status 
(ClinicalTrials.gov Identifier: NCT01459484). However, in this trial, which is presently ongoing 
and recruiting patients, ABCB1 expression level is used to stratify HGOS patients but not as 
therapeutic target. 
 A possible strategy to overcome the clin cal resistance against doxorubicin may be based on 
the use of ABC transporter inhibitors, with the aim to revert doxorubicin-resistant tumour cells 
toward a drug-sensitive phenotype. Although several ABC transporter inhibitors have entered 
phase I-II-III trials for different human tumours, their clinical use has invariably been limited by 
the severe toxicity exerted at the concentrations required to efficiently inhibit ABC transporter 
activity [4]. In the past ten years, in order to overcome this limitation, a new generation of ABC 
transporter inhibitors has been developed and characterised [4], showing promising preclinical 
results also in HGOS cells [3]. 
In the next years, this new generation of ABCB1 inhibitors might therefore provide novel agents 
that may be considered for doxorubicin-unresponsive HGOS patients. 
 An alternative strategy that has been suggested to overcome the ABCB1-mediated drug 
resistance may be based on the use of curcumin, a phenolic compound used in the traditional 
indian medicine, which was shown to down-modulate the function of ABCB1 and to partially 
revert doxorubicin resistance in human HGOS cell lines [3]. Some years ago, curcumin was 
included in a phase I-II clinical trial for relapsed or metastatic HGOS patients (ClinicalTrials.gov 
Identifier: NCT00689195). The recruitment status of this trial is unfortunately unknown and no 
































































results have been posted yet. It is therefore impossible to understand whether this approach might 
be of help to overcome the ABCB1-mediated drug resistance in HGOS patients.  
 Another additional possibility to interfere with ABCB1 activity in human tumour cells has 
been highlighted by recent studies on protein kinase inhibitor drugs. Some of them proved to 
downregulate ABCB1 activity and, therefore, act as chemoresistance revertants [5]. We have 
recently provided evidence that this situation also occurs in HGOS cells, and that the combined 
treatment of specific kinase inhibitor drugs with doxorubicin can overcome the ABCB1-mediated 
drug resistance in human HGOS cell lines [6, 7]. This may represent a real perspective of 
intervention to improve the treatment response and outcome of doxorubicin-resistant HGOS 
patients. 
 Doxorubicin-unresponsive HGOS patients may be also treated with alternative, 
conventional chemotherapeutic drugs. There are, in fact, clinical studies demonstrating that HGOS 
patients may be efficiently treated with etoposide, methotrexate, and ifosfamide [8, 9]. 
In a French randomized trial that enrolled 234 children/adolescents with localized HGOS, the 
efficacy of preoperative chemotherapy with high-dose methotrexate plus doxorubicin was 
compared to that of high-dose methotrexate plus etoposide and ifosfamide [8]. A good histological 
response (tumour necrosis greater than 95%) was achieved in 56% of the etoposide-ifosfamide 
arm patients versus 39% of the doxorubicin arm (P = 0.009). Although no significant difference 
was found regarding five-year event-free and overall survival between the two protocol arms, this 
study showed that treatment with methotrexate, etoposide and ifosfamide is effective and can lead 
to survival rates similar to those achievable with standard regimens based on methotrexate and 
doxorubicin. 
The same group also performed the multicenter OS2006 phase III study, which enrolled 318 
HGOS patients and was primarily aimed to assess the efficacy of zoledronic acid [9]. Preoperative 
chemotherapy addressed to pediatric patients consisted in methotrexate, ifosfamide and etoposide, 
whereas adult patients received ifosfamide, doxorubicin and cisplatin. Patients with a good 
histological response received a postoperative treatment with the same drugs as in the preoperative 
phase. Poor responder pediatric patients were treated with a regimen in which ifosfamide and 
etoposide were replaced by cisplatin and doxorubicin, whereas poor responder adult patients 
received etoposide plus ifosfamide. Patients were randomly assigned to receive the 
aforementioned chemotherapy with or without ten zoledronate intravenous infusions.  
Unfortunately, the addition of zoledronic acid did not improve treatment efficacy and prognosis, 
but the observation that the rate of good histological response was higher in patients treated with 
































































methotrexate, ifosfamide and etoposide compared to those who received ifosfamide, doxorubicin 
and cisplatin, confirmed the previous findings reported by the same group [8]. 
 Approaches based on the use of doxorubicin derivatives aiming to improve the local 
efficacy of the native drug, have also been considered to treat unresponsive, relapsed HGOS 
patients.   
Doxil (liposomal doxorubicin hydrochloride) is a liposomal encapsulated doxorubicin with a 
longer half-life in blood and an improved drug incorporation into tumour cells. 
Doxil was first used in a group of 47 sarcoma patients (including six HGOS) who were 
unresponsive to doxorubicin and standard chemotherapy [10]. Clinical benefit was observed in 
three of the six HGOS patients. All of them had previously received doxorubicin and ifosfamide, 
indicating that doxil may be considered for treating patients refractory to conventional doxorubicin 
[10]. 
After this study, doxil has been considered for other clinical trials for patients with HGOS 
(ClinicalTrials.gov Identifiers: NCT00949325; NCT00019630; NCT02557854).  
The NCT00949325 phase I/II trial has been performed to test the ability of temsirolimus (CCI-
779; an mTOR inhibitor) to potentiate the cytotoxic effect of liposomal doxorubicin [11]. This 
trial, which enrolled 15 bone and soft-tissue sarcoma patients (including one patient with HGOS), 
showed that the combination of liposomal doxorubicin with temsirolimus can be safely 
administered to heavily pretreated patients with recurrent or refractory bone and soft tissue 
sarcomas and that the toxicity of this combination was manageable and reversible [11]. The 
NCT00019630 phase I trial has been completed, but no study results have been posted yet.  
The NCT02557854 phase I trial is not open yet for recruitment. Its estimated primary completion 
date is December 2018.  
Although there is some evidence that doxil could be a possible alternative drug to native 
doxorubicin, it is still too early to define its actual value for treating doxorubicin-resistant HGOS 
patients. 
More recently, aldoxorubicin (formerly DOXO-EMCH, then renamed as INNO-206), an albumin-
binding prodrug of doxorubicin with acid-sensitive properties, has emerged as an agent superior to 
native doxorubicin in several preclinical tumour models [12]. Phase I and II studies showed that 
aldoxorubicin was able to induce tumour regression in breast cancer, small cell lung cancer, and 
sarcomas [13]. Aldoxorubicin also appeared to be more effective than doxorubicin in advanced 
soft-tissue sarcoma patients [14], despite  producing a higher incidence of grade 3-4 neutropenia 
[15]. In the past years, trials based on the use of aldoxorubicin alone or in combination with other 
chemotherapeutic drugs have been launched for treating patients with advanced solid tumours and 
































































sarcomas. However, most of them have been either completed without providing results 
(ClinicalTrials.gov Identifiers: NCT01337505, NCT01673438) or are active but not recruiting 
patients (ClinicalTrials.gov Identifiers: NCT02049905, NCT02235688). At present, there is one 
phase I/II trial (ClinicalTrials.gov Identifier NCT02235701) that is recruiting participants. Its 
completion date is scheduled for December 2018. This trial is aimed to investigate the safety and 
activity of aldoxorubicin plus ifosfamide/mesna in patients with metastatic, locally advanced, or 
unresectable soft-tissue sarcomas and it may provide information which can be of interest also for 
HGOS. However, similarly to doxil, the actual clinical value of aldoxorubicin in HGOS still needs 
to be established. 
 Other chemically modified doxorubicins have recently been developed and proved to be 
effective against drug-resistant tumour cells overexpressing ABCB1 [16, 17]. A mitochondria-
targeting doxorubicin recently proved to be more effective and less cardiotoxic than doxorubicin 
in murine osteosarcoma preclinical models and to overcome the ABCB1-mediated doxorubicin 
resistance in HGOS cell lines [16]. 
Other compounds obtained by combining doxorubicin with H2S donors through an ester linkage 
at C-14 showed to be less cardiotoxic to in vitro cultured cardiomyocytes and more active than the 
native drug also in ABCB1-overexpressing, doxorubicin-resistant human HGOS cell lines [17]. 
These findings indicate these doxorubicin derivatives as promising new chemotherapeutic drugs 
for a possible future clinical application in doxorubicin-unresponsive HGOS patients. 
 Very recently, the progress of nanomedicine has offered new hope for improving 
chemotherapeutic drug efficacy, as well as for overcoming chemotherapy resistance and reducing 
collateral toxicities. Nanomedicine techniques have also been applied to doxorubicin, in order to 
increase its in vivo stability and to control its intracellular drug release. 
Although this approach has not specifically been studied in HGOS, findings provided in other 
human tumours have indicated that the nanodrug delivery system may be a promising selective 
modality to overcome the ABCB1-mediated doxorubicin resistance [18, 19], and to improve its 
treatment efficacy by simultaneously reducing the risk for cardiotoxicity [20]. 
As representative examples, we briefly mention here two doxorubicin nanoassemblies that have 
emerged as promising candidates for being transfered into clinical settings. 
Using a so-called “squalenoylation” technology, doxorubicin can be chemically linked onto 
squalene, a natural lipid precursor of the cholesterol biosynthesis. The resulting squalenoyl 
doxorubicin proved to improve doxorubicin response of human tumour cells both in in vitro and in 
vivo experimental models, as well as to reduce the cardiotoxicity compared to the native 
doxorubicin [21]. 
































































Of particular interest for a possible clinical application in the near future is the very recent 
development of an injectable nanoparticle generator (iNPG) which can be loaded with poly(l-
glutamic acid)-conjugated doxorubicin (pDox) [22]. The resulting iNPG-pDox was able to 
overcome multiple biological barriers to cancer drug delivery and resistance. In fact, it has been 
shown that, after intravenous injection, iNPG-pDox accumulated at tumours and released pDox 
nanoparticles that were internalised by neoplastic cells. Intracellularly, pDox nanoparticles were 
transported to the perinuclear region and cleaved into doxorubicin, thereby avoiding excretion by 
drug efflux pumps like ABCB1 [22]. 
 Finally, novel indications for modulating HGOS patients' treatment may derive from 
pharmacogenomic studies. Several tumour (somatic) and normal cell (germline) markers have 
been suggested to modulate responsiveness to conventional chemotherapeutic drugs in HGOS. 
Although pharmacogenomic studies in HGOS are still at their beginning, some interesting 
evidence has already emerged (reviewed in:  [23]).  
The role of somatic ABCB1 overexpression in HGOS cells for doxorubicin resistance is well 
understood, whereas there is less consensus regarding the impact of germline ABC transporter 
polymorphisms for patients with HGOS ([23] and references therein). Among the transporter 
genes involved in doxorubicin transport, ABCB1_rs1128503 was reported to correlate variably 
with response to combined doxorubicin chemotherapy and survival in HGOS ([23] and references 
therein). ABCC2_rs717620 was associated with poor histological response and a decreased risk 
for hematological or liver toxicity, and ABCC3_rs939338 with worse outcome ([23] and 
references therein). Moreover, in a recent study, ABCC2_rs2273697 was associated with poor 
survival and an increased risk for hematological toxicity [24]. However, it should be noted that in 
none of these studies toxicity was evaluated in relation to doxorubicin cycles alone. Therefore, 
these polymorphisms might be associated with the combined effect of all the drugs administered.  
In one study, evaluating toxic events also in relation to doxorubicin alone, the variant 
GSTP1_rs1695 was associated with increased risk of leukopenia and cardiotoxicity [25]. Other 
genes with reported clinical impact in HGOS patients in relation to doxorubicin belong mainly to 
several DNA repair pathways and drug metabolising enzymes ([23] and references therein).  
Recent pharmacogenetic investigations have tried to identify genomic risk factors for 
anthracycline-induced cardiotoxicity in children ([26] and references therein). Although several 
germline variants have been reported in transporter, carbonyl reductase genes and the hyaluron 
synthase 3 gene, none of them can currently be used in clinical routine to tailor doxorubicin 
therapy. More studies are necessary to identify those genomic variants that are invariably 
































































associated with toxicity caused by doxorubicin treatment in HGOS patients, in order to suggest 
them for either modified doxorubicin or alternative drugs. 
Although almost all the described genomic variants need to be functionally characterised before 
their possible translation to the clinical setting, once validated, they will drive the transition to 
genetically guided decisions for personalised therapies. This approach, using the patients' 
pharmacogenomic background to optimise the treatment efficacy, is expected to overcome the 
present limitations of standard clinical procedures, which modulate drug dosage on the basis of 
patients' body surface area and age without considering the fact that patients inherently have 
different capabilities to metabolise and respond to chemotherapeutic agents. 
 In conclusion, since new promising agents and therapeutic strategies, which may overcome 
resistance against doxorubicin in HGOS and other musculo-skeletal tumours, are currently under 
development and evaluation, it is possible to speculate that outcomes of these patients will 
reasonably improve in the near future. 
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